Outlook Therapeutics Inc
NASDAQ:OTLK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tibet Aim Pharm Inc
SZSE:002826
|
CN |
|
BHG Group AB
STO:BHG
|
SE |
|
Escalade Inc
NASDAQ:ESCA
|
US |
Outlook Therapeutics Inc
EPS (Diluted)
Outlook Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Outlook Therapeutics Inc
NASDAQ:OTLK
|
EPS (Diluted)
-$1
|
CAGR 3-Years
35%
|
CAGR 5-Years
25%
|
CAGR 10-Years
43%
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Outlook Therapeutics Inc
Glance View
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 9 full-time employees. The company went IPO on 2016-06-13. The firm focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. ONS-5010, is the Company's product candidate, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. Its clinical program for ONS-5010 in wet AMD involves three clinical trials, which includes NORSE ONE, NORSE TWO and NORSE THREE. Outlook sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets for the treatment of wet AMD, diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).
See Also
What is Outlook Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-1.7
USD
Based on the financial report for Dec 31, 2025, Outlook Therapeutics Inc's EPS (Diluted) amounts to -1.7 USD.
What is Outlook Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
43%
Over the last year, the EPS (Diluted) growth was 12%. The average annual EPS (Diluted) growth rates for Outlook Therapeutics Inc have been 35% over the past three years , 25% over the past five years , and 43% over the past ten years .
